vs
Side-by-side financial comparison of AC Immune SA (ACIU) and ASTRAZENECA PLC (AZN). Click either name above to swap in a different company.
ASTRAZENECA PLC is the larger business by last-quarter revenue ($14.5B vs $1.4M, roughly 10063.3× AC Immune SA). ASTRAZENECA PLC runs the higher net margin — 16.9% vs -1622.4%, a 1639.4% gap on every dollar of revenue. On growth, AC Immune SA posted the faster year-over-year revenue change (90.1% vs 11.7%).
AC Immune SA is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics and diagnostic solutions for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and rare tauopathies. It operates globally, partners with leading pharmaceutical enterprises, and prioritizes addressing unmet medical needs in neurological care segments.
AstraZeneca plc (AZ) is a Swedish-British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
ACIU vs AZN — Head-to-Head
Income Statement — Q2 2025 vs Q2 2025
| Metric | | |
|---|---|---|
| Revenue | $1.4M | $14.5B |
| Net Profit | $-23.3M | $2.4B |
| Gross Margin | — | 82.9% |
| Operating Margin | -1484.5% | 24.3% |
| Net Margin | -1622.4% | 16.9% |
| Revenue YoY | 90.1% | 11.7% |
| Net Profit YoY | 6.9% | 27.0% |
| EPS (diluted) | — | $1.57 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $1.4M | $14.5B | ||
| Q2 24 | $755.7K | $12.9B | ||
| Q2 23 | — | $11.4B | ||
| Q3 22 | $4.3M | — | ||
| Q2 22 | — | $10.8B |
| Q2 25 | $-23.3M | $2.4B | ||
| Q2 24 | $-25.0M | $1.9B | ||
| Q2 23 | — | $1.8B | ||
| Q3 22 | $-14.9M | — | ||
| Q2 22 | — | $360.0M |
| Q2 25 | — | 82.9% | ||
| Q2 24 | — | 83.1% | ||
| Q2 23 | — | 82.8% | ||
| Q3 22 | — | — | ||
| Q2 22 | — | 72.2% |
| Q2 25 | -1484.5% | 24.3% | ||
| Q2 24 | -3051.1% | 21.2% | ||
| Q2 23 | — | 21.5% | ||
| Q3 22 | -342.2% | — | ||
| Q2 22 | — | 5.0% |
| Q2 25 | -1622.4% | 16.9% | ||
| Q2 24 | -3313.0% | 14.9% | ||
| Q2 23 | — | 15.9% | ||
| Q3 22 | -343.6% | — | ||
| Q2 22 | — | 3.3% |
| Q2 25 | — | $1.57 | ||
| Q2 24 | — | $1.24 | ||
| Q2 23 | — | $1.17 | ||
| Q3 22 | — | — | ||
| Q2 22 | — | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $28.3M | $7.1B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $82.2M | $44.8B |
| Total Assets | $209.2M | $112.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $28.3M | $7.1B | ||
| Q2 24 | $56.7M | $6.9B | ||
| Q2 23 | — | $5.7B | ||
| Q3 22 | $49.0M | — | ||
| Q2 22 | — | $4.8B |
| Q2 25 | $82.2M | $44.8B | ||
| Q2 24 | $135.8M | $39.6B | ||
| Q2 23 | — | $37.4B | ||
| Q3 22 | $209.1M | — | ||
| Q2 22 | — | $36.0B |
| Q2 25 | $209.2M | $112.4B | ||
| Q2 24 | $261.3M | $104.3B | ||
| Q2 23 | — | $96.5B | ||
| Q3 22 | $226.1M | — | ||
| Q2 22 | — | $96.6B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
